Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
124 Results for "
integrin αv
" in MedChemExpress (MCE) Product Catalog:
Products (124)
124 Results for "integrin αv" in MCE Product Catalog:
Cat. No.: HY-16142
CAS No.: 188969-00-8
Synonyms: EMD 121974 hydrochloride
Target:
Research Areas:
Cilengitide hydrochloride (EMD 121974 hydrochloride) is an integrin (integrin) inhibitor with blood-brain barrier permeability, with IC50 values against human targets as follows: 0.61 nM for αvβ3, 8.4 nM for αvβ5, 14.9 nM for α5β1, 5400 nM for αIIbβ3, 2050 nM for αvβ6, 2350 nM for αvβ8. Cilengitide hydrochloride inhibits the binding of integrins to vitronectin, fibronectin, fibrinogen and LAP (TGF-β), and serves as an internal standard for solid-phase integrin binding assays. Cilengitide hydrochloride inhibits tumor cell viability, induces apoptosis, reduces the phosphorylation levels of STAT3, AKT and mTOR, downregulates the expression of PD-L1, inhibits cell viability and angiogenesis, regulates anti-tumor immune responses and slows tumor growth. Cilengitide hydrochloride can be used in research related to glioblastoma, melanoma, advanced solid tumors and refractory brain tumors .
Cat. No.: HY-P11576
CAS No.: 2089299-82-9
Research Areas:
Cyclic αvβ6 (Compound c(FRGDLAFp(NMe)K)) is a αvβ6-integrin-specific cyclic nonapeptide. Cyclic αvβ6 can be coupled with 68Ga-labeled monomeric triazacyclononane-triphosphinate (TRAP). Cyclic αvβ6 can be used in PET imaging studies for cancers including head and neck cancer and pancreatic cancer .
Cat. No.: HY-P11773
CAS No.: 1094848-94-8
Research Areas:
Cat. No.: HY-P11708
CAS No.: 2708163-13-5
Cat. No.: HY-P3335
CAS No.: 250612-06-7
Synonyms: DOTA-RGDfK dimer
Research Areas:
Cat. No.: HY-100506R
CAS No.: 1320346-97-1
Target:
Research Areas:
GLPG0187 (Standard) is the analytical standard of GLPG0187 (HY-100506). This product is intended for research and analytical applications. GLPG0187 is a broad spectrum integrin receptor antagonist with antitumor activity; inhibits αvβ1-integrin with an IC50 of 1.3 nM . GLPG0187 inhibits migrasome biogenesis without cytotoxicity .
Cat. No.: HY-100563AR
CAS No.: 217099-14-4
Target:
Research Areas:
Cat. No.: HY-100563R
CAS No.: 250612-42-1
Target:
Research Areas:
Cat. No.: HY-P10704A
Cat. No.: HY-184578
Target:
Research Areas:
DOPE-PEG1000-cRGD is a functionalized PEGylated lipid conjugate composed of three modular components: dioleoylphosphatidylethanolamine (DOPE) as the lipid anchoring group, a polyethylene glycol (PEG) spacer arm with a molecular weight of 1000 Da, and cyclic RGD peptide (cyclo(Arg-Gly-Asp)) as the terminal targeting/functional ligand. DOPE-PEG1000-cRGD can be incorporated into liposomes, lipid nanoparticles (LNPs), or other nanocarriers to confer ligand-directed targeting capability against αvβ3/αvβ5 integrins on tumor vasculature and cancer cell surfaces.
Cat. No.: HY-184578A
Target:
Research Areas:
DOPE-PEG2000-cRGD is a functionalized PEGylated lipid conjugate composed of three modular components: dioleoylphosphatidylethanolamine (DOPE) as the lipid anchoring group, a polyethylene glycol (PEG) spacer arm with a molecular weight of 2000 Da, and cyclic RGD peptide (cyclo(Arg-Gly-Asp)) as the terminal targeting/functional ligand. DOPE-PEG2000-cRGD can be incorporated into liposomes, lipid nanoparticles (LNPs), or other nanocarriers to confer ligand-directed targeting capability against αvβ3/αvβ5 integrins on tumor vasculature and cancer cell surfaces.
Cat. No.: HY-184578B
Target:
Research Areas:
DOPE-PEG3400-cRGD is a functionalized PEGylated lipid conjugate composed of three modular components: dioleoylphosphatidylethanolamine (DOPE) as the lipid anchoring group, a polyethylene glycol (PEG) spacer arm with a molecular weight of 3400 Da, and cyclic RGD peptide (cyclo(Arg-Gly-Asp)) as the terminal targeting/functional ligand. DOPE-PEG3400-cRGD can be incorporated into liposomes, lipid nanoparticles (LNPs), or other nanocarriers to confer ligand-directed targeting capability against αvβ3/αvβ5 integrins on tumor vasculature and cancer cell surfaces.
Cat. No.: HY-184578C
Target:
Research Areas:
DOPE-PEG5000-cRGD is a functionalized PEGylated lipid conjugate composed of three modular components: dioleoylphosphatidylethanolamine (DOPE) as the lipid anchoring group, a polyethylene glycol (PEG) spacer arm with a molecular weight of 5000 Da, and cyclic RGD peptide (cyclo(Arg-Gly-Asp)) as the terminal targeting/functional ligand. DOPE-PEG5000-cRGD can be incorporated into liposomes, lipid nanoparticles (LNPs), or other nanocarriers to confer ligand-directed targeting capability against αvβ3/αvβ5 integrins on tumor vasculature and cancer cell surfaces.
Cat. No.: HY-184579
Target:
Research Areas:
DMG-PEG1000-cRGD is a functionalized PEGylated lipid conjugate composed of three modular components: dimyristoylglycerol (DMG) as the lipid anchoring group, a polyethylene glycol (PEG) spacer arm with a molecular weight of 1000 Da, and cyclic RGD peptide (cyclo(Arg-Gly-Asp)) as the terminal targeting/functional ligand. DMG-PEG1000-cRGD can be incorporated into liposomes, lipid nanoparticles (LNPs), or other nanocarriers to confer ligand-directed targeting capability against αvβ3/αvβ5 integrins on tumor vasculature and cancer cell surfaces.
Cat. No.: HY-184579A
Target:
Research Areas:
DMG-PEG2000-cRGD is a functionalized PEGylated lipid conjugate composed of three modular components: dimyristoylglycerol (DMG) as the lipid anchoring group, a polyethylene glycol (PEG) spacer arm with a molecular weight of 2000 Da, and cyclic RGD peptide (cyclo(Arg-Gly-Asp)) as the terminal targeting/functional ligand. DMG-PEG2000-cRGD can be incorporated into liposomes, lipid nanoparticles (LNPs), or other nanocarriers to confer ligand-directed targeting capability against αvβ3/αvβ5 integrins on tumor vasculature and cancer cell surfaces.
Cat. No.: HY-184579B
Target:
Research Areas:
DMG-PEG3400-cRGD is a functionalized PEGylated lipid conjugate composed of three modular components: dimyristoylglycerol (DMG) as the lipid anchoring group, a polyethylene glycol (PEG) spacer arm with a molecular weight of 3400 Da, and cyclic RGD peptide (cyclo(Arg-Gly-Asp)) as the terminal targeting/functional ligand. DMG-PEG3400-cRGD can be incorporated into liposomes, lipid nanoparticles (LNPs), or other nanocarriers to confer ligand-directed targeting capability against αvβ3/αvβ5 integrins on tumor vasculature and cancer cell surfaces.
Cat. No.: HY-184579C
Target:
Research Areas:
DMG-PEG5000-cRGD is a functionalized PEGylated lipid conjugate composed of three modular components: dimyristoylglycerol (DMG) as the lipid anchoring group, a polyethylene glycol (PEG) spacer arm with a molecular weight of 5000 Da, and cyclic RGD peptide (cyclo(Arg-Gly-Asp)) as the terminal targeting/functional ligand. DMG-PEG5000-cRGD can be incorporated into liposomes, lipid nanoparticles (LNPs), or other nanocarriers to confer ligand-directed targeting capability against αvβ3/αvβ5 integrins on tumor vasculature and cancer cell surfaces.
Cat. No.: HY-187237A
Target:
Research Areas:
DPPE-PEG2000-cRGD is a functionalized PEGylated lipid conjugate composed of three modular components: dipalmitoylphosphatidylethanolamine (DPPE) as the lipid anchoring group, a polyethylene glycol (PEG) spacer arm with a molecular weight of 2000 Da, and cyclic RGD peptide (cyclo(Arg-Gly-Asp)) as the terminal targeting/functional ligand. DPPE-PEG2000-cRGD can be incorporated into liposomes, lipid nanoparticles (LNPs), or other nanocarriers to confer ligand-directed targeting capability against αvβ3/αvβ5 integrins on tumor vasculature and cancer cell surfaces.
Cat. No.: HY-187244A
Target:
Research Areas:
DSG-PEG2000-cRGD is a functionalized PEGylated lipid conjugate composed of three modular components: distearoylglycerol (DSG) as the lipid anchoring group, a polyethylene glycol (PEG) spacer arm with a molecular weight of 2000 Da, and cyclic RGD peptide (cyclo(Arg-Gly-Asp)) as the terminal targeting/functional ligand. DSG-PEG2000-cRGD can be incorporated into liposomes, lipid nanoparticles (LNPs), or other nanocarriers to confer ligand-directed targeting capability against αvβ3/αvβ5 integrins on tumor vasculature and cancer cell surfaces.
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
